CRTC1 and non-small cell lung carcinoma: We elucidated the regulatory mechanism of CRTC1-mediated immune evasion in NSCLC and propose that CRTC1-targeted inhibitors may serve as a potent therapeutic strategy to enhance patient sensitivity to anti-PD-L1 therapy.